Skip to content

Study · Not a test of the peptide alone · 2022

4 results

The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review.

Ng NBH, Low YW, Rajgor DD, Low JM, Lim YY, Loke KY, Lee YS

Clinical endocrinology26 Aug 2021Cited by 33 (Europe PMC)

PMID34448208 (opens in a new tab)DOI10.1111/cen.14583 (opens in a new tab)PepBankPUB-34448208
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In 23 patients with Prader-Willi syndrome, pooled GLP-1 receptor agonist use (exenatide or liraglutide) was followed by BMI improvement in ten patients, from 1.5 to 16.0 kg/m2.

    In plain wordsIn 23 people with Prader-Willi syndrome who used exenatide or liraglutide, BMI improved in ten of them.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI improvement
    Study

    n = 23

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    BMI improvement range
    1.5 to 16 kg/m2
    pooled GLP1-RA

    Source sentences

    Summary
    Ten patients experienced improvement in body mass index, ranging from 1.5 to 16.0 kg/m2
    1 context sentence
    Summary · context
    Ten studies included, summarizing GLP1-RA use in 23 PWS patients (age, 13-37 years), who had used either exenatide (n = 14) or liraglutide (n = 9) over a duration of 14 weeks to 4 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In 23 patients with Prader-Willi syndrome, pooled GLP-1 receptor agonist use (exenatide or liraglutide) was followed by HbA1c improvement in 19 of 23 cases, from 0.3% to 7.5%.

    In plain wordsIn 23 people with Prader-Willi syndrome who used exenatide or liraglutide, HbA1c improved in 19 of them.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c improvement
    Study

    n = 23

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Patients with HbA1c improvement
    19 patients
    pooled GLP1-RA
    HbA1c improvement range
    0.3 to 7.5%
    pooled GLP1-RA

    Source sentences

    Summary
    improvement in HbA1c was seen in 19 of 23 cases, ranging between 0.3% and 7.5%.
    1 context sentence
    Summary · context
    Ten studies included, summarizing GLP1-RA use in 23 PWS patients (age, 13-37 years), who had used either exenatide (n = 14) or liraglutide (n = 9) over a duration of 14 weeks to 4 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In patients with Prader-Willi syndrome, no serious side effects were reported with pooled GLP-1 receptor agonist use (exenatide or liraglutide).

    In plain wordsIn people with Prader-Willi syndrome who used exenatide or liraglutide, no serious side effects were reported.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerious side effects
    Study

    n = 23

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    There were no reported serious side effects.
    1 context sentence
    Summary · context
    Ten studies included, summarizing GLP1-RA use in 23 PWS patients (age, 13-37 years), who had used either exenatide (n = 14) or liraglutide (n = 9) over a duration of 14 weeks to 4 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In patients with Prader-Willi syndrome, all five studies of pooled GLP-1 receptor agonists (exenatide or liraglutide) that reported appetite or satiety showed improved satiety.

    In plain wordsIn people with Prader-Willi syndrome, all five studies that reported satiety found it improved with exenatide or liraglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseSatiety
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    All five studies reporting appetite or satiety showed improvement in satiety levels.
    1 context sentence
    Summary · context
    Ten studies included, summarizing GLP1-RA use in 23 PWS patients (age, 13-37 years), who had used either exenatide (n = 14) or liraglutide (n = 9) over a duration of 14 weeks to 4 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.